Ceylan HEPOKUR, Sema MISIR, Mahmut ÖZBEK

A-Fact’ın hemostatik etkileri

Amaç: A-Fact demir(II) sülfat içeren bir çözelti olup, demir-iyon-protein kompleksi oluşturur. İdeal bir hemostatik ajan lezyona uygulandıktan sonra venöz kanamayı durdurmalıdır. Bu çalışma A-Fact’ın muhtemel kanama durdurucu etkisini göstermek ve in vitro olarak hemostatik parametreler üzerine etkilerini belirlemek amacıyla yapıldı. Yöntem: Gönüllü insanlardan alınan venöz kan örneklerinden santrifüj edilerek plazma havuzu oluşturuldu. A-Fact’ın farklı konsantrasyonları uygulanılarak total protein, fibrinojen aktivitesi, albümin ve globulin, koagülasyon faktör (II, VII, IX) düzeyleri oto analizöründe spektrofotometrik yöntem ile analiz edildi. Morfolojik değerlendirme için kan örneklerine % 5, % 10, % 15 ve % 50 A-fact uygulanılarak mikroskobik görüntüleri alındı. Bulgular: A-Fact demir-iyon-protein kompklesinin oluşumunu sağladı. Koagülasyon testleri 2/20 dilüsyon yapılarak gerçekleştirildi. A-Fact’ın koagülasyon faktörleri üzerinde herhangi bir etkisinin olmadığı gözlendi. Plazma fibrinojen aktivitesi, total protein, albümin ve globulin düzeyleri azalırken buna paralel olarak protrombin zamanı uzadı. Ayrıca, A-Fact’ın INR değerlerinde artışa neden olduğu gözlendi. Sonuç: Bu çalışma ile A-Fact’ın kanama durdurucu etkisinin protein ağı oluşumu üzerinden olabileceği sonucuna varıldı. Bu alanda daha ileri çalışmalara ihtiyaç olduğu açıktır.

Hemostatic effects of A-Fact

Objective: A-Fact is a solution contains iron (II) sulfate and forms an iron-ion-protein complex. An ideal hemostaticagent should have been stopping venous bleeding after being applied to the lesion. Our aim in the present study is toinvestigate the in vitro effects of A-Fact on hemostatic parameters.Method: Plasma pooling was performed by centrifuging venous blood samples from volunteer people. Total protein,fibrinogen activity, albumin and globulin, coagulation factor (II, VII, IX) levels were analyzed with spectrophotometricmethod in auto analyzer by applying different concentrations of A-Fact. Microscopic images were obtained by applying5%, 10%, 15% and 50% A-fact to blood samples for morphological evaluation.Results: A-Fact ensured the formation of the iron-ion-protein complex. Coagulation tests were performed by 2/20dilution. A-Fact was not effect on coagulation factors. Plasma fibrinogen activity, total protein, albumin and globulinlevels were decreased while prothrombin time was prolonged. Furthermore, it was observed that A-Fact caused anincrease in INR values.Conclusions: In this study, it was showed that the bleeding-stopping effect of A-Fact may be caused by proteinformation. It is clear that further studies are needed in this area.Keywords: A-Fact, Kanama Durdurucu, Iron (II) Sulfate

PDF

___

Ferhanoğlu B. Hemostaz Mekanizması. Hematoloji Ders Kitabı. ISBN: 978-975-404-815- 5.Üniversite Yayın No: 4774.Cerrahpaşa Tıp Fak. Yayın No: 269:Istanbul, 2008,p.219- 227.
Colman RW, Hırsh J, Moider VJ. Hemostasis and Trombosis, Basic Principles and Clinical Practise.6th ed.USA: Lippincott Williams,2004,p.381-400.
Carmona RH, Lim RC, Clark GC. Morbidity and mortality in hepatic trauma. Am J Surg 1982;144:88-94.
Kaynaroğlu ZV. Karın travmaları. Ed:Sayeki. Temel cerrahi.3th ed. Ankara: Güneş kitabevi. 2004,466-472.
Parks RW, Chrysos E, Diamond T. Management of liver trauma. Br J Surg 1999; 86: 1121-1135.
Secer HI, Daneyemez M, Tehli O, Gonul E, Izci Y. The clinical, electrophysiologic, and surgical characteristics of peripheral nerve injuries caused by gunshot wounds in adults: a 40-year experience. SurgNeurol 2008;69:143-52.
Sönmez E, Çavuş UY, Civelek C, Dur A, Karayel E, Gülen B, Uysal Ö, İpek G. The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model. Ulus Travma Acil Cerr Derg March 2014; 20: 2.
Kurata M, Horii I. Blood coagulation tests in toxicological studies review of methods and their significance for drug safety assesment. J.Toxical Sci 2004;29:13-32.
Daniel NG, Goulet J, Bergeron M, Paquin R, Landry Pe. Antitrombosit Drugs:ıs there a surgical risk? J can dent Assoc 2002;68:683-687.
Degroot Pg, Sixma Jj. Trombosit Adhesion. Br J haematol 1990; 75:308-312.
Goker H, Haznedaroglu IC, Ercetın S, Kırazlı S, Akman U, Ozturk Y, Hc Fırat HC. Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper. The Journal of International Medical Research 2008; 36:163-170.
Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. British Journal of Surgery 2008; 95: 1197-1225.
Pogorielov MV, Sikora VZ. Chitosan as a Hemostatic Agent: Current State. European Journal of Medicine. Series B, 2015, Vol.(2), Is. 1.
Lapierre F, Houtaud SD, Wager M, Hemostatic Agents in Neurosurgery. Explicative Cases of Controversial Issues in Neurosurger 2011,doi:10.5772/31319.
Uzun N, Tanriverdi T, Savrun FK, Kiziltan ME, Sahin R, Hanimoglu H, et al. Traumatic peripheral nerve injuries: demographic and electrophysiologic findings of 802 patients from a developing country. J ClinNeuromuscul Dis 2006;7:97-103.
Vance GN and Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845– 850.
Jankun J, Landeta P, Pretorıus E, Skrzypczak-Jankun E, Lıpınskı B. Unusual clotting dynamics of plasmasupplemented with iron(III). Internatıonal Journal Of Molecular Medıcıne 2014; 33: 367-372.
Clark WR, Leather RP, Hemostasis during liver resections. Surgery 1970;67:5556- 5576.
Evans BE. Local hemostatic agents. N.Y. J. Dent 1977; 47: 109-14.
Bleeding Control and Healing Aid Compositions and Methods of Use, Terence Prevendar, US 6,652,840 B1, Nov. 25, 2003.
Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil 2008;87:381-5.
Al B, Yildirim C, Cavdar M, Zengin S, Buyukaslan H, Kalender ME. Effectiveness of Ankaferd blood stopper in the topical control of active bleeding due to cutaneous-subcutaneous incisions. Saudi Med J 2009; 30: 1520–5.
Vance GN, Etheresia P. Iron-enhanced coagulation is attenuated by chelation:a thrombelastographic and ultrastructural analysis. Blood Coagulation and Fibrinolysis 2014;25:845– 50.
Aysan E, Bektas H, Ersoz F, Sari S, Kaygusuz A, Huq GE. Ability of the ankaferd blood stopper® to prevent parenchymal bleeding in an experimental hepatic trauma model. Int J Clin Exp Med 2010; 3: 186–91. 2.
Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329–36. 3.
Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011; 17: 3962–70. 4.
Tasdelen Fisgin N, Tanriverdi Cayci Y, Coban AY, Ozatli D, Tanyel E, Durupinar B, Tulek N. Antimicrobial activity of plant extract Ankaferd Blood Stopper. Fitoterapia 2009; 80: 48–50. 5.
Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, Turan SA. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010; 5: 110. 6.
Yüce S, Çandirli C, Yenidünya S, Muslu B. New hemostatic agent: the effect of Ankaferd Blood Stopper on healing wounds in experimental skin incision model. Turk J Med Sci 2014; 44: 288-294.